Related Experiment Video
Updated: Apr 21, 2026

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
Intravitreal ranibizumab for choroidal neovascularization secondary to choroidal nevus
Benjamin Guigui1, Eric H Souied, Salomon Yves Cohen
1From the *Centre Ophtalmologique d'Imagerie et de Laser, Paris, France; and †University Eye Clinic, Creteil, France.
Purpose:
To describe a patient treated with ranibizumab for juxtafoveal choroidal neovascularization secondary to choroidal nevus.
Methods:
A 71-year-old man presented with juxtafoveal choroidal neovascularization secondary to choroidal nevus. Choroidal neovascularization was initially treated with a single intravitreal injection of ranibizumab.
Results:
The treatment was successful and best-corrected visual acuity improved from 20/50 to 20/25 and remained stable during 7 months. A recurrence was observed 9 months after initial treatment.
Conclusion:
Ranibizumab seems to be an effective treatment for choroidal neovascularization secondary to choroidal nevus. However, late recurrence may occur.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Diabetic Retinopathy
Angle Closure Glaucoma: Treatment

